Freenome, Inc. (FRNM) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Freenome, Inc. (FRNM) stock forecast summary
On Oct. 16, 2026, FRNM is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Freenome, Inc. is a small-cap company with a market capitalization of $1.26B. It ranks number 14 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for FRNM is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FRNM included.
Follow FRNM freeFRNM price chart and AI forecast
How FRNM ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Freenome, Inc. (FRNM) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | FRNM | Rank |
|---|---|---|
| Market Cap | $1.26B | 14/29 |
Profitability & Margins
| Metric | FRNM | Rank |
|---|---|---|
| ROA | -1.9% | 6/20 |
| ROIC | -5.3% | 10/24 |
Financial Health
| Metric | FRNM | Rank |
|---|---|---|
| Current Ratio | 0.20x | 24/26 |
| Working Capital | -$3M | 22/26 |
Cash Flow
| Metric | FRNM | Rank |
|---|---|---|
| Operating Cash Flow | -$910K | 14/27 |
Income Statement
| Metric | FRNM | Rank |
|---|---|---|
| Operating Income | -$4M | 11/26 |
| Net Income | -$2M | 6/20 |
Dividend & Shareholder Information
| Metric | FRNM | Rank |
|---|---|---|
| Shares Outstanding | 107M | – |
| Net Income Growth | -168.5% | 5/5 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $740K | |
| Cash & Short-term Investments | $440K | |
| Total Liabilities | $7M |
FRNM quarterly financials and insider trading
Freenome, Inc. (FRNM) industry peers
Companies classified under the same SEC industry code as Freenome, Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| FRNM Freenome, Inc. | ▶ | $1.26B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $78M |
| MDXH Mdxhealth Sa | ▶ | $58M |
| CFOR Capforce Inc. | ▶ | $43M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▶ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where FRNM sits on the market map
Freenome, Inc. (FRNM) stock news
Loading...
Freenome, Inc. (FRNM) stock forecast FAQ
What is the Freenome, Inc. (FRNM) stock forecast?
On Oct. 16, 2026, FRNM is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Freenome, Inc. stock predictions?
A per-ticker accuracy statistic for FRNM is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Freenome, Inc. forecasts updated?
Freenome, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Freenome, Inc.'s industry peers?
30 issuers in our coverage, FRNM included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.